NASDAQ •
Healthcare •
Diagnostics & Research •
Quote as of 06/17/2026 16:00
Company Profile
IndustryDiagnostics & Research
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4.91 mln
Float4.42 mln
Earnings Date08/14/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-3.2
Reliable
Relative Strength
1
/ 100
Severely lagging
Debt / Equity
0.38
Low leverage
ROE
-415
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
bioAffinity Technologies is a San Antonio-based company focused on catching lung cancer early, before it becomes harder to treat. Their main product, CyPath Lung, examines a patient's mucus sample to identify cells that suggest the presence of a lung tumor, all without the need for invasive procedures. Founded in 2014, the company combines laboratory services with ongoing research to improve how lung diseases are detected and understood.
